Dan Zhang, M.D., Ph.D.

Peking Union Innovation Hub is an incubator to transform the basic research into clinical application. It has its own VC and its discovery, clinical and manufacturing platform to serve all the biotech and medical device firms to speed up their R&D and commercialization process by leveraging Peking Union Medical School/Chinese Academy of Medial Science’s existing 21 research institutes and 6 top-tier medical centers. 

Greater Bay Area Research Institute of Precision Medicine is focusing on the basic discovery and translational research for innovative biological product dealing with unmet medical need;

Clinical Research Institute of Fudan University is working on the training of clinical research scientists and supports all clinical research and clinical trial operations within 19 affiliated teaching hospitals of the Shanghai Medical University of Fudan University. 

Hillgene Biopharma Co., Ltd. is a CDMO (Contract Development and Manufacturing Organization) focusing on CGT product . The company operates full production lines and service centers in Suzhou, China, and Brussels, Belgium, serving clients across China, Europe, North America, and Southeast Asia. It provides plasmid, viral vector, and cell development and manufacturing services that meet ICH quality standards. Our team in Brussels has operated for three-years and incubated EsoBiotec for its in vivo BCMA CAR-T product with IIT clinical data generated from China, which was licensed to AstraZeneca for USD 1 billion.

Fountain Medical Development Ltd. (now  ClinChoice Medical Development Co., Ltd.) is a full-service CRO (Contract Research Organization) established with support from the Ministry of Science and Technology, the National Health Commission, the Ministry of Commerce, the NMPA, and Tianjin Municipality, as well as renowned U.S. venture capital firms such as Goldman Sachs and Lilly Asia Ventures. The company offers comprehensive clinical development services, including Phases I to IV trials and regulatory submissions. Through organic growth and two U.S.-based acquisitions, it has established branches in Beijing, Tianjin, Nanjing, Shanghai, Guangzhou, Wuhan, Shenyang, Chengdu, Taipei, Seoul, Hong Kong, Armenia, Japan, India, the UK, Italy, Germany, the Philippines, Canada, and the U.S. The company has more than 4500 employees and serves over 500 leading global biopharma, diagnostics, and medical device companies, as well as 120 innovative Chinese pharmaceutical firms and research institutions. Over the past five years, it has completed 70 NDA/BLA filings in the US FDA and with 59 approvals

Prior to founding Fountain Medical, Dan Zhang was responsible for clinical development, drug safety evaluation, project management, and business development for North America at Sigma-Tau, one of Italy’s largest pharmaceutical companies with over 2,500 employees. During his tenure, he completed six INDs and one NDA submissions in the U.S., and successfully licensed oncology and heart failure products to Novartis Oncology, DebioPharm, and Lee’s Pharmaceutical for development and marketing rights across Europe, North America, and Greater China.

Earlier, Dan Zhang pioneered the Greater China operations for Quintiles Transnational Corp. (now IQVIA after merging with IMS), serving as its first Greater China Chairman and later as Vice President and Executive Committee Member from 1995 to 2000. IQVIA is the world’s largest CRO with over 58,000 employees globally.

Dr. Zhang has provided consulting services to global enterprises on drug pricing, health economics, drug development, and market strategy. His clients include Eli Lilly, Pharmacia, Medtronic, Pfizer, CIGNA, etc..

Currently, Dr. Zhang serves as:

• • Chairman of the Scientific Advisory Board of Frost & Sullivan （Frost & Sullivan Greater China Special Contribution Award (2024)）
  • Forbes China 2025 Industry Pioneer Leader
  • Chairman of the ICH E19 IFPMA Expert Working Group

• Member of the NMPA ICH Task Force

Educational Background:

Dr. Dan Zhang received his MD from Peking Union Medical College in 1989. Then he received his MPH degree from Harvard School of Public Health and master degree in healthcare management from the Wharton School of the University of Pennsylvania, . He is currently pursuing a Ph.D. in Finance at the Wharton.